The FDA has approved Vertex Pharmaceuticals’ Journavx, a new pain medication designed to reduce the risk of addiction and overdose associated with opioids. Intended for short-term pain after surgeries or injuries, the drug offers a novel approach by blocking pain signals before they reach the brain, unlike opioids that bind to brain receptors.
Though clinical trials showed moderate effectiveness compared to opioid-acetaminophen pills, experts highlight the drug’s potential due to its unique mechanism and reduced risk of abuse. Common side effects include nausea, constipation, and headaches.
Despite high hopes, Vertex’s stock fell after disappointing trial results for chronic nerve pain. However, the company plans further studies to seek approval for broader pain management applications.
FingerLakes1.com is the region’s leading all-digital news publication. The company was founded in 1998 and has been keeping residents informed for more than two decades. Have a lead? Send it to [email protected].